Lilly’s Cyramza closer to first-line lung cancer use after ODAC verdictEli Lilly’s cancer drug Cyramza has inched closer to a new indication in first-line non-small cell lung cancer Share XLilly’s Cyramza closer to first-line lung cancer use after ODAC verdicthttps://pharmaphorum.com/news/lilly-closes-on-first-line-lung-cancer-use-after-odac-verdict/
Trial answers the KRAS question for Keytruda in lung cancerMerck & Co’s Keytruda reigns supreme among immunotherapies for non-small cell lung cancer (NSCLC), and new data looks Share XTrial answers the KRAS question for Keytruda in lung cancerhttps://pharmaphorum.com/news/trial-answers-the-kras-question-for-keytruda-in-lung-cancer/
Roche steps up Merck challenge with first-line NSCLC approval in USRoche has scored another FDA approval for Tecentriq alongside chemotherapy for previously-untreated, non-squamous non-small cell lung cancer (NSCLC), Share XRoche steps up Merck challenge with first-line NSCLC approval in UShttps://pharmaphorum.com/news/roche-continues-merck-challenge-with-first-line-nsclc-approval-in-us/
Takeda sets sights on first-line lung cancer market with new Alunbrig dataPfizer’s ALK inhibitor Xalkori is facing a further challenge from Takeda newcomer Alunbrig, which outperformed it in a Share XTakeda sets sights on first-line lung cancer market with new Alunbrig datahttps://pharmaphorum.com/news/takeda-sets-sights-on-first-line-lung-cancer-market-with-new-alunbrig-data/
Finally, AZ claims a win with Imfinzi/tremelimumab cancer comboAstraZeneca’s development of checkpoint inhibitor combination Imfinzi and tremelimumab has chalked up serial trial failures in the last Share XFinally, AZ claims a win with Imfinzi/tremelimumab cancer combohttps://pharmaphorum.com/news/finally-az-claims-a-win-with-imfinzi-tremelimumab-cancer-combo/
BMS gets a much-needed win with Opdivo in first-line lung cancerBristol-Myers Squibb’s attempts to challenge Merck & Co’s dominance in previously-untreated non-small cell lung cancer (NSCLC) have disappointed Share XBMS gets a much-needed win with Opdivo in first-line lung cancerhttps://pharmaphorum.com/news/bms-gets-a-much-needed-win-with-opdivo-in-first-line-lung-cancer/
Relief for Lilly as drug from $8bn Loxo deal clears pivotal trialEli Lilly’s $8 billion acquisition of Loxo Oncology looks like it could pay off, with new data for Share XRelief for Lilly as drug from $8bn Loxo deal clears pivotal trialhttps://pharmaphorum.com/news/relief-for-lilly-as-drug-from-8bn-loxo-deal-clears-pivotal-trial/
MSD’s Keytruda plus chemo backed by NICE for lung cancerMerck & Co/MSD’s Keytruda can be provided via the Cancer Drugs Fund for first-line treatment of non-small cell Share XMSD’s Keytruda plus chemo backed by NICE for lung cancerhttps://pharmaphorum.com/news/msds-keytruda-plus-chemo-backed-by-nice-for-lung-cancer/
NICE clears front-line NHS use for Pfizer’s lung cancer drug VizimproPfizer has stolen a march on rival AstraZeneca in the first-line non-small cell lung cancer category, after NICE Share XNICE clears front-line NHS use for Pfizer’s lung cancer drug Vizimprohttps://pharmaphorum.com/news/nice-clears-front-line-nhs-use-for-pfizers-lung-cancer-drug-vizimpro/
